Adjuvant treatment for chromophobe kidney cancer – pro
While first line pembrolizumab is effective in chrmophome cancers of the kidney, there is much elss evidence for effectiveness for chromophobe cancers. Chromophobe renal cell carcinoma (chRCC) is the third most common type of RCC with distinct biology compared to other kidney cancer subtypes. The recent review article by Gerje et al says that: ” Currently, there is no role for adjuvant therapy after definitive surgery for stages I-III chRCC. :.
Romero, D. First-line pembrolizumab plus lenvatinib is effective in non-clear-cell RCC. Nat Rev Clin Oncol 20, 661 (2023).
Rohan Gerje et al, Comprehensive review of chromophobe renal cell carcinoma. Critical Reviews in Oncology/Hematology Volume 160 , April 2021, 103287